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Abstract
Background: Noncompliance to treatment assignment is an inevitable occurrence in randomized clinical trials
(RCTs). Intention to treat (ITT) is generally considered the best method for addressing noncompliance in RCTs.
Alternatives to ITT exist, including per protocol (PP), as treated (AT), and instrumental variables (IV). These three
methods define participant compliance dichotomously, but partial compliance is a common occurrence in RCTs.
By defining a threshold, above which a participant is called a complier, PP, AT and IV can be used, but the resulting
loss of information may affect their performance. Trials with factorial designs may experience higher rates of
noncompliance due to the heavier burden that participants experience by being assigned to multiple experimental
treatments.
Methods: Using simulations, we assessed the performance of ITT, PP, AT, and IV in both the partial compliance setting
and in a 2-by-2 factorial design with increased participant burden for those randomized to both active treatments.
Results: The bias, mean squared error, and type I error rates of the IV method after dichotomizing partial compliance
were heavily inflated. The performance of all four methods depended on the level of noncompliance present, with
higher average noncompliance leading to poorer performance. PP and AT showed improved bias and power relative
to ITT without inflating the type I error beyond acceptable limits. However, the PP and AT heavily inflated the type I
error rates when participant compliance was affected by the participants’ general health.
Conclusions: There are consequences for dichotomizing compliance information to make it fit into well-known
methods. The results suggest the need for a method of estimating treatment effects that can utilize partial compliance
information.
Background
Participant noncompliance is inevitable in clinical trials
and must be considered by researchers in order to ap-
propriately interpret data. Noncompliance exists when a
participant does not comply with assigned treatment but
remains in the study, diluting the differences between
treatment groups and thereby affecting the power of a
superiority study [1]. Thus, participant noncompliance is
an issue that should be considered during both the de-
sign and analysis phases of a clinical trial. Methods have
been developed to estimate a treatment effect in the
presence of participant noncompliance.
The most common method employed to deal with non-
compliance is intention to treat (ITT), which is considered
by many to be the gold standard [2]. ITT simply analyzes
participants as randomized, regardless of the actual treat-
ment received. The drawback to ITT is that it may not
measure the true effect of the treatment being studied [3].
Alternatives to ITT that attempt to find the true treatment
effect include the per protocol (PP), as treated (AT), and
instrumental variables (IV) methods. All three methods
assume compliance is measured dichotomously but may
be adapted for use when compliance is measured on a
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continuous scale. However, employing these methods in
this manner may affect their estimation of the treatment
effect.
Many increasingly complex methods of estimating
treatment effects in the presence of noncompliance have
been proposed. Imbens and Rubin proposed a method
that imputes a participant’s latent compliance status (the
participant’s possible compliance with either treatment)
using Bayesian methods [4]. This work was extended to
partial compliance by Jin and Rubin [5]. Nagelkerke et
al. proposed adding an indicator of the treatment re-
ceived and the residuals from a regression of the treat-
ment received on the treatment assigned into regression
models [6]. Efron and Feldman reframe the issue of par-
tial compliance into a dose–response setting, but have
the added complexity of participant self-selected doses
as opposed to the randomly assigned doses employed in
typical dose–response trials [7]. However, these methods
are incredibly complex theoretically and in practice, and
they may be too daunting for a researcher who has not
extensively studied them to employ.
Other issues with compliance may arise depending on
the design of the trial. One design that can lead to a
unique compliance situation is the factorial design, in
which participants are assigned to treatment levels for
multiple therapies simultaneously. Since some partici-
pants are asked to receive multiple therapies, a factorial
design can place a heavier burden on participants than a
study of only one therapy. Furthermore, the experimen-
tal treatments being studied may place a heavier burden
on participants than the control. In this case, a factorial
design may compound the burden placed on the partici-
pants, especially among those randomized to multiple
active treatment arms. Placing participants under higher
burdens can have the expected effect of increasing non-
compliance to treatment assignment for all the treat-
ments in the study.
In this paper, we will assess the performance of the ITT,
PP, AT, and IV methods for estimating a treatment effect
in the presence of noncompliance measured on a continu-
ous scale using simulations. Additionally, the performance
of ITT, PP, AT, and IV will be assessed when employed in
a two-by-two factorial design that places heavier burdens
on participants in the experimental arms.
Methods
Noncompliance methods
Suppose that a clinical trial is designed to test the differ-
ence in two means with the hypotheses H0 : μ0 = μ1 ver-
sus Ha : μ0 ≠ μ1. If there is participant noncompliance in
the study, then a noncompliance method must be
employed in order to determine whether to reject the al-
ternative hypothesis. ITT, PP, AT, and IV are four such
methods that can be employed to test the hypothesis.
The ITT method is employed by simply disregarding
whether a participant complied with assigned treatment
and analyzing the participant as if he/she had fully com-
plied with the assigned treatment. Using ITT, the esti-
mation of the mean treatment effect is then the
difference in the average outcomes (δ) of the participants
who were assigned to the treatment and the participants
assigned to the control:
δITT ¼ μ1−μ0 ð1Þ
ITT is very simple to implement while preserving the
randomization employed by the trial. Since ITT groups
participants as they are randomized (and hence by
assigned treatment), when there is noncompliance
among the treated group, this estimate is not a true
measure of the treatment effect. Instead, ITT measures
the effect of treatment assignment on the outcome of
interest [3].
The PP method removes noncompliant participants
from the analysis, which ensures that all participants in-
cluded were fully compliant to their assigned treatment.
Thus, the PP estimate of treatment effect is as follows:
δPP ¼ μ1c−μ0c ð2Þ
where μ1c is the average outcome for participants
assigned to the experimental treatment who complied
with the treatment. μ0c is defined similarly for those in
the control group.
AT deals with noncompliance by grouping participants
for analysis based on the treatment actually received and
ignores assigned treatment. Assuming that noncompli-
ance only occurs when the participant receives the other
treatment group’s therapy, the AT estimate of treatment
effect is then determined as follows:




where μ1n is the average outcome of the participants
who were assigned to the experimental treatment and
did not comply. μ0n is the average outcome of the non-
compliant participants in the control arm of the study,
whereas μ1c and μ0c are defined as above.
Both PP and AT attempt to estimate the true treat-
ment effect using intuitive and easy to implement
methods; however, both are problematic from an analyt-
ical perspective. Unless participant noncompliance is
completely random, employing PP will remove a sub-
population of the study population for whom the treat-
ment may perform poorly (or perhaps better). Thus, the
PP method may lead to biases in estimates, in addition
to the possibility of introducing imbalances of covariates
between treatment groups. AT explicitly breaks the
randomization scheme of the study and allows the non-
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compliant participants to effectively self-select their
treatment, which also introduces the possibility of biases
in the estimation [8].
Another method for estimating the treatment effect in
the presence of noncompliance is the instrumental vari-
ables (IV) method. Briefly, an instrumental variable is a
variable that does not directly affect the outcome of
interest except through the predictor of interest. In the
application of the IV method, treatment assignment is
considered an instrumental variable affecting the out-
come of interest only through its impact on the treatment
the participant actually receives. By using an instrumental
variable, the approach attempts to remove the effects of
the confounders that affect both a participant’s compli-
ance and outcome [9]. In practice, this method inflates the
ITT estimate by a factor of the estimated proportion of la-
tent compliers (participants who would have complied




where π^ c is the estimate of the proportion of latent
compliers in the study,




n1 is the total number of participants in the experimental
group and n1n is the number of non-compliant partici-
pants in the experimental group. n0 and n0n are defined
similarly for the control group. Since the IV method em-
ploys the ITT estimate, participants remained grouped as
randomized, so it avoids the problems inherent in the PP
and AT methods. The IV method does have its own draw-
backs though, such as that one of the assumptions for
employing IV is that noncompliance only occurs in one
direction [9]. That is, participant noncompliance will con-
sist of either switching on to the experimental treatment
for those in the control group or switching off of the ex-
perimental treatment from the experimental group, but
not both.
PP, AT, and IV all assume that compliance to assigned
treatment is binary: either a participant is or is not com-
pliant. This may be a reasonable way to model compli-
ance in studies of some therapies, but many treatments
studied in clinical trials are administered multiple times
over a period. Drug and behavioral interventions are
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Fig. 1 Type I error rate of each noncompliance method across four compliance distributions (reference line provides result for fully
compliant population)
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possible for a participant to be neither fully compliant nor
fully noncompliant to the treatment assignment, but
merely partially compliant. Thus, in order for PP, AT, and
IV to be employed as methods for estimating the treat-
ment effect in the presence of partial compliance, partici-
pants’ compliance status must first be dichotomized. This
is generally done by choosing a level of partial compliance
(such as 80 %), above which, a participant is considered
compliant, and below which, he is considered noncompli-
ant. Dichotomizing the compliance level of participants
may have a steep cost through a loss of information, which
may lead to a loss of power and thus introduce bias into
the estimate of treatment effect.
Simulation
In order to assess the effect of dichotomizing compli-
ance on the estimation of treatment effect when ITT, PP,
AT, and IV are employed, we simulated two-arm studies
(N = 128) in which some participants were partial com-
pliers. We assumed normally distributed outcomes with
a shared variance of σ2 = 2 and a true treatment effect of
δ = 1. The sample size was chosen for a balanced study
able to detect the treatment effect with at least 80 %
power. We assumed participants assigned to the control
arm of the study did not have access to the experimental
treatment, and hence, the only noncompliance observed
was in the experimental arm of the study. For each par-
ticipant in the experimental arm of the study, the level
of compliance for each participant was drawn from a
distribution with possible values ranging from 0 to 1.
Four different compliance situations were examined
using different distributions of the compliance: three
Beta distributions (α = 1 β = 0.1765, α = 0.25 β = 0.05,
and α = 0.5 β = 0.5), and a uniform distribution on [0,1].
An additional file shows the distribution of samples from
each of the four distributions (see Additional file 1). The
Beta (1, 0.1765) and Beta (0.25, 0.05) distributions repre-
sented situations where compliance was reasonably good
(with expected compliance of 85 % and 83 %, respectively),
as well as heavily clustered around 0 (complete noncom-
pliance) and 1 (complete compliance). The Beta (0.5, 0.5)
distribution and the uniform distribution both represented
situations where the average proportion of noncompliance
was much higher. In addition, because these two different
distributions have the same expected compliance level
(50 %) but different shapes, a comparison of these two
compliance situations provided insight into the perform-
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Fig. 2 Power of each noncompliance method across four compliance distributions (reference line provides result for fully compliant population)
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increased noncompliance. It was assumed that the effect
of the experimental treatment was in proportion to the
amount of treatment received as a function of compliance,
so a participant assigned to the active treatment arm that
only received 50 % of the assigned treatment (that is, 50 %
compliant) had an expected change in outcome of 0.5.
To dichotomize the participants’ partial compliance,
cutoff points were chosen above which the participant
was considered compliant to the assignment. A wide
range of cutoff points were considered for each set of
simulated data: 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85,
and 0.9.
After the participants were grouped as compliant or
noncompliant based on the cutoff point, the four
methods of interest were then applied to estimate the
treatment effect from the simulated data. ITT, PP, and
AT were simply applied as described above. The IV esti-
mate was computed by dividing the ITT estimate by the
proportion of participants labeled as compliant in the
experimental group, which is an estimate of the propor-
tion of latent compliers.
The average bias and mean squared error (MSE) were
calculated for each of the methods, for each combination
of cutoff point and compliance distribution. Further-
more, a two-tailed t-test was used to test the null
hypothesis of no treatment difference. The power of the
test was calculated as the proportion of the simulations
for which the null hypothesis was rejected in favor of
the alternative. The average bias, MSE, and power were
assessed using 1000 replications. In order to assess the
type I error rate, the simulations were repeated with no
treatment effect (δ = 0). The type I error rate was then
the proportion of simulations for which the null hypoth-
esis was rejected. Type I error was assessed using 5000
replications.
Since in the above simulation, participant compliance
was sampled completely independently of other factors,
the assumptions required for PP and AT to be unbiased
are met. Another set of simulations were run in order to
assess the performance of all the methods when partici-
pant compliance is not independent. In this simulation,
an untreated outcome for all participants was sampled
from a normal distribution with a mean of 0 and vari-
ance 2. Participants with untreated outcomes below the
25th percentile were presumed to be sicker, and their
compliance was sampled from distribution with a lower
mean than those with higher untreated outcomes. The
healthy group’s mean compliance was 0.8, whereas the
sicker group had a mean of 0.7. The variance of the
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Fig. 3 Biases of each noncompliance method across four compliance distributions (reference line provides result for fully compliant population)
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simulation were collected similarly to the previously de-
scribed simulation.
The effect of the increased noncompliance resulting
from increased burden in factorial designs was assessed
by simulating a balanced 2 × 2 factorial design with a
sample size of 128, chosen so that there was 80 % power
to detect a treatment effect of specified size in one arm.
Since we were interested in how the noncompliance in
the more heavily burdened treatment group affected the
estimate of treatment effect in comparison to a simple
two-arm study, it was assumed that only one of the
treatments being investigated in the factorial design had
an effect on the participants’ outcome. Furthermore, it
was assumed that the association between treatment
level and outcome was not a function of the treatment
level of the other treatment (that is, no treatment inter-
action). Participant outcomes were sampled from the
normal distribution with a shared variance of 2 and a
true treatment effect of 1, similar to the two-arm study
simulation.
To represent increased noncompliance because of the
increased burden placed on participants, the distribution
of compliance depended on the treatment group. As in
the two-arm simulation, it was assumed that participants
assigned to the control group of the therapy of interest
could not switch on to the experimental treatment and
were thus fully compliant. Compliance for participants
that were assigned to the experimental arm of the treat-
ment of interest and the control arm of the other ther-
apy was sampled from a Beta distribution with a mean
of 0.9 and variance 1/12 representing relatively high
compliance to assigned treatment. Participants in the ex-
perimental arms of both studies were placed under a
heavier burden, and thus the compliance distributions
were also Beta distributions with lower means to repre-
sent the potentially lower compliance. Three different
Table 1 Relative mean squared error (MSE) by method, cutpoint, and compliance distribution (relative to intention to treat (ITT))
Cutpoint Method Compliance distribution
Beta (1, 0.1765) Beta (0.25, 0.05) Beta (0.5, 0.5) Uniform
0.9 PP 1.064 0.951 0.991 2.251
AT 1.148 0.898 1.023 2.365
IV 2.598 1.508 17.183 173.917
0.85 PP 1.024 0.930 0.863 1.390
AT 1.081 0.868 0.905 1.504
IV 2.004 1.434 8.887 44.182
0.8 PP 0.998 0.915 0.760 1.050
AT 1.025 0.847 0.793 1.160
IV 1.671 1.366 5.543 18.681
0.75 PP 0.985 0.918 0.690 0.866
AT 1.001 0.856 0.712 0.981
IV 1.469 1.313 3.833 9.308
0.7 PP 0.954 0.913 0.658 0.795
AT 0.959 0.853 0.682 0.912
IV 1.336 1.274 2.858 5.467
0.65 PP 0.944 0.909 0.637 0.720
AT 0.944 0.851 0.656 0.835
IV 1.242 1.245 2.230 3.476
0.6 PP 0.933 0.900 0.616 0.667
AT 0.927 0.845 0.635 0.779
IV 1.172 1.218 1.818 2.369
0.55 PP 0.933 0.898 0.607 0.651
AT 0.927 0.848 0.619 0.745
IV 1.127 1.190 1.555 1.763
0.5 PP 0.931 0.904 0.592 0.641
AT 0.924 0.857 0.603 0.720
IV 1.092 1.171 1.362 1.386
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situations were considered: small (mean = 0.8), larger
(mean = 0.6), and extreme (mean = 0.4) drops in com-
pliance, relative to those in a single treatment arm
(mean = 0.9). The variance of the increased burden
compliance distributions were all 1/12.
The partial compliance was dichotomized in this
situation using the same range of cutoff points as in
the two-arm simulation. ITT, PP, AT, and IV were
then employed as described previously to estimate the
treatment effect of the therapy of interest. Average
bias and MSE of the estimates were calculated, and the
power and type I error rate of the test of significance of
the estimate of treatment effect were assessed as they were
in the two-arm simulations. A total of 1000 replicated
datasets for each situation were generated in order to
calculate the average bias, MSE and power. A total of
5000 datasets were generated to calculate the type I
error rate.
Results
Two-arm study, compliance independent of disease
burden
The type I error rate for each test when δ = 0 is pre-
sented in Fig. 1. The ITT method controlled the type I
error rate very well, staying very close to the nominal
level of 0.05. In all cases, except those for which the cut-
off point was close to 1, the PP and AT methods also
controlled the type I error rate reasonably well. On the
other hand, the IV method inflated the type I error rate;
in some cases, the inflation was extreme. For the com-
pliance distributions with a mean of 0.5, the results of
the IV method are not pictured in order to keep the fig-
ure to an appropriate scale. For both distributions with
mean 0.5 and all cutoff points, the type I error rate with
the IV method never fell below 30 % and rose as high as
nearly 85 % in the case of uniform compliance with a
cutoff of 0.9.
The power of the test for each method is presented in
Fig. 2. The power for all four methods was tied to the
amount of noncompliance in the study. When employ-
ing ITT, the power was significantly reduced when a
large amount of noncompliance (for example, 50 % non-
compliance) was present in the study. Even when com-
pliance was better in the study though, ITT still had
lower power than the other three methods. The IV
method generally had the highest power of the methods,
and it increased as the cutoff point approached 1. PP
generally had higher power than AT, but both performed
relatively similarly in comparison to ITT and IV; both
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Fig. 4 Type I error rates of each noncompliance method when compliance is related to untreated outcomes
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The average bias of each of the methods for the different
compliance distributions in the two-arm study simulation
is presented in Fig. 3. The same general relationship
between the four methods was preserved across all compli-
ance distributions. As expected, ITT consistently underesti-
mated the true treatment effect and was unaffected by the
choice of cutoff point for dichotomization (since it did not
take compliance into account). The bias of the ITT esti-
mate was affected by the mean level of compliance in the
study population, but not the shape of the distribution.
Hence, the bias of ITT was similar for both the uniform
distribution and the Beta (0.5, 0.5) distribution. Both PP
and AT also consistently underestimated the treatment ef-
fect as well, but both were closer than ITT. The average
bias of both PP and AT was also relatively static with regard
to the cutoff point chosen by the investigators. The IV
estimator performed quite differently. IV generally overesti-
mated the treatment effect, and the bias increased expo-
nentially as the cutoff point approaches 1. The strength of
the IV estimate’s bias varied greatly depending on the distri-
bution of the compliance. IV performed better when the
distribution of the compliance is clustered around 0 and 1
(that is, there was generally a clear distinction between a
“complier” and a “noncomplier”).
The MSE of the methods in each compliance distribu-
tion in the two-arm study simulation is presented in
Table 1. The IV estimate consistently had the highest
MSE of the four methods, while also increasing expo-
nentially as the cutoff point approached 1. The ITT
method generally had the second highest MSE, while AT
and PP performed similarly to each other. It can be
noted that the MSE for both AT and PP do increase as
the cutoff point approaches 1, but not nearly at the rate
at which IV increased.
Comparing the uniform compliance situation with the
Beta (0.5, 0.5) situation, the PP, AT, and IV methods all
performed better in the Beta (0.5, 0.5) situation where
participant compliance tended to either 0 or 1. The re-
sults for ITT are similar to each other for both compli-
ance distributions since they have the same mean level
noncompliance. The bias in the PP and AT methods was
similar in each situation, but each method experienced
higher variance (reflected in the increased MSE) in the
uniform distribution. The higher variance predictably
led to lower power and higher type I error rates for both
methods, especially at higher cutoff points. The IV
method had similar results as PP and AT in comparing
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Fig. 5 Biases of each noncompliance method when compliance is related to untreated outcomes
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variance of the estimate was much more dramatic. Add-
itionally, the IV method did have a notable increase in
bias in the uniform compliance situation when com-
pared to the Beta (0.5, 0.5) situation.
Two-arm study, compliance as a function of disease
burden
The type I error rates when the sicker participants had
lower compliance levels are presented in Fig. 4. ITT con-
tinues to maintain a type I error rate close to 0.05, while
the IV method has inflated type I error rates as before.
However, PP and AT both have inflated type I error rates
that grow more extreme as the compliance level for the
sicker group drops and the cutoff point increases, with
AT having higher type I error rates than PP. Both
methods even have type I error rates greater than that of
IV as compliance among the sicker group drops.
Figure 5 presents the biases of each method when
sicker participants experience lower compliance. Once
again, ITT and IV perform similarly to the first simula-
tion, underestimating and overestimating the treatment
effect respectively. In this situation though, PP and AT
generally overestimate the treatment effect as opposed
to underestimating it in the first simulation. Both over-
estimate the bias to a greater degree in the situations
with higher cutoff points and lower compliance among
the sicker participants.
Factorial design
The results of the type I error rate for each method
with higher burden due to being assigned the experi-
mental treatment in both arms of a factorial study
are presented in Fig. 6. The ITT, PP, and AT are simi-
lar regardless of the level of compliance for the par-
ticipants experiencing higher burden from multiple active
treatments. The IV method had drastically increased type
I error rates as the compliance in the increased burden
group decreased.
The power of each method in the factorial study simu-
lation is presented in Fig. 7. The effect of higher partici-
pant burden on ITT was very strong, with power
dropping to about 40 % when the burden was extremely
heavy. The PP and AT methods also have reduced power
as the compliance of the participants in the higher bur-
den group decreases, but both have higher power than
ITT in each situation observed. The IV method is less
affected by the level of compliance in the higher burden
group than the other methods. As compliance drops, the
power when using the IV method may be reduced either
when a low cutoff point is used or increased when a high
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Fig. 6 Type I error of each noncompliance method across participant burden levels
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The effect of higher participant burden in the factorial
study simulation on the bias of each method is presented
in Fig. 8. The bias of the ITT method is affected by the
higher burden, decreasing as participants on two active
treatments experience lower levels of compliance. The
IV method appears to experience increased positive bias
as compliance in the higher burden group decreases.
However, the biases of both PP and AT are compara-
tively not affected by the amount of compliance in the
increased burden group.
Table 2 presents the relative MSE results for the fac-
torial study simulation. The PP and AT methods gener-
ally had smaller MSE than ITT. Higher burden levels
further widened the gap between the ITT method and
the AT and PP methods. In comparison, the MSE using
the IV method is higher than the ITT method’s MSE
with the difference accentuated by increasing participant
burden.
Discussion
The results of the simulation study in the two-arm case
reveal why ITT has endured as the assumed gold stand-
ard method of estimating a treatment effect in the pres-
ence of participant noncompliance in a superiority trial.
The ITT method is always biased towards the hypothesis
of no treatment effect, which is commonly the null
hypothesis of the study question. In this case, employing
ITT to estimate the treatment effect will not inflate the
type I error rate of the test. This great benefit of ITT
comes at the cost of the power of the study, however.
The strength of the bias of ITT, and hence the amount
of the loss of power in the study, is directly tied to the
amount of noncompliance in the study. If a study has
only a small amount of noncompliance, the loss of
power may be negligible; but if enough noncompliance is
present, the loss of power may be drastic. PP and AT pro-
vided a little benefit over employing ITT in any of the sit-
uations observed. In fact, both of the methods may
perform poorly in comparison to ITT in some situations
when the cutoff point was close to 1, and both have the
ability to introduce additional biases into the analyses.
The clearest conclusion from the results of the simu-
lations is that employing the IV method with partial
compliance by first dichotomizing the compliance
measure is inappropriate. In this situation, IV will con-
sistently overestimate the treatment effect for most cut-
off points that are greater than 0.5. Additionally, in a
truly dichotomous compliance setting, IV generally has
the highest variance of these four methods [4], and that
remains true in the partial compliance setting as well.
These issues with IV mean that testing with this
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Fig. 7 Power of each noncompliance method across participant burden levels
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error rates, and thus it cannot be recommended that IV
be used in this manner.
The decision of where the cutoff point is for dichot-
omizing a collected partial compliance measure in order
to employ PP, AT, or IV can have a strong effect on the
estimation. It is clear that if “compliance” is defined
stringently by choosing the cutoff point to be close to 1,
all three methods will perform poorly. In addition, the
distribution of participant compliance plays an import-
ant role in the performance of the three methods that
dichotomize the compliance. PP, AT, and IV all had bet-
ter performance under compliance distributions that are
clustered around 0 and 1. Since dichotomizing under
these compliance distributions is more natural, this re-
sult is not unexpected. The effect of clustering in the
distribution on the methods’ performance is best seen
by comparing the uniform distribution compliance
with the Beta (0.5, 0.5) distribution compliance. Both
distributions have the same mean compliance level of
0.5, but the Beta distribution has clustering around 0
and 1. As we would expect, all the methods perform
poorly under both compliance distributions because
of the fairly high level of noncompliance, but PP, AT,
and IV all perform worse under the uniform distribu-
tion than the Beta distribution.
While the performance of both PP and AT is reason-
able when compliance is independent of other factors,
the situation when compliance is related to other patient
characteristics is much worse. In the simulated situation,
PP and AT will tend to remove or regroup participants
in the experimental arm with lower outcomes since they
will also generally have lower compliance as well. This
inflates the average outcome in the experimental arm
and leads to overestimation of the treatment effect and
that in turn to inflated type I error rates. Since partici-
pant compliance being completely independent to other
participant characteristics is highly unlikely, the use of
PP and AT will likely provide suspect results.
The effect of increased participant burden is straight-
forward. The issues that each method experienced in the
two-arm study are intensified. Hence the ITT method’s
power drops precipitously, and the IV method’s type I
error inflation becomes more drastic as the participant
burden increases. PP and AT perform relatively well in
this setting, but there is still a loss of power incurred
when the burden increases even for these methods.
These simulations assumed that only participants in
the experimental arm could truly be noncompliant. This
means that control arm participants did not have access
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any placebo being used in the control arm had a negli-
gible effect on participants’ outcomes. However, if the
experimental treatment is freely available, control arm
noncompliance by switching onto the experimental
treatment may occur. This study did not investigate
these situations, but it is assumed that similar results
that are heightened by the average treatment effect of
both treatment arms being affected by participant non-
compliance may occur.
Simulations in this study assumed that there is a linear
relationship between the level of compliance to the ac-
tive treatment and the observed outcome, but possibly,
for some treatments, the relationship may be different.
Different relationships may alter the effect of the choice
of cutpoint for dichotomization on the results. For ex-
ample, if the effect of the treatment plateaus at 80 %
compliance, then 80 % would be a natural cutpoint for
dichotomization. In this case, more stringent definitions
of compliance may have even stronger negative conse-
quences than what is observed in the simulations pre-
sented in this paper. Further research into the different
relations between compliance and observed outcomes
would provide greater understanding into the role the
relation plays in the performance of methods for dealing
with noncompliance.
Dichotomization is the most extreme method of cat-
egorizing continuous compliance data. Categorizing into
more than two groups may reduce the strength of the ef-
fect of choosing cutpoints in the results, as well as being
able to more accurately represent a wider variety of
compliance distributions. However, categorizing compli-
ance into more than two groups is very rarely discussed
in the literature. The development of statistical methods
that can use such categorization of compliance are a
possible avenue for future research.
Conclusions
Measures of participant compliance to assigned treat-
ment that are collected in a clinical trial are often con-
tinuous values. However, the most commonly known
methods for addressing noncompliance in a trial as-
sumed that compliance is binary. This paper used simu-
lations to investigate the performance of ITT, PP, AT,
and IV after dichotomizing partial compliance measures.
The results of the simulations indicated that the use of
PP and AT provides little benefit to estimating treatment
effect over the gold standard of ITT when used with di-
chotomized compliance data, while using the IV method
with dichotomized data often led to unacceptably in-
flated type I error rate. Choosing a stringent definition
of compliance may also lead to inflated type I error rates
for the PP and AT methods, especially if the distribution
of the compliance does not cluster around 0 or 1. Simu-
lations investigating the possible of effects of reduced
compliance for participants on two active treatments in
a factorial design study were also created. The results of
the simulations are similar to the results in a two-arm
trial. The increased burden for participants in a factorial
design study mainly affected the results through the in-
creased level of overall noncompliance in the study
population.
No statistical method can improve on keeping partici-
pants compliant, and researchers must take care during
the design and execution of their trial to address compli-
ance issues before or as they arise. When noncompliance
occurs though, it is important to choose a method that
is appropriate for the situation at hand. The results of
this study suggest that methods that can account for the
partial compliance information should be an improve-
ment over adapting the information to fit into well-
Table 2 Relative mean square error (MSE) by method, cutpoint,
and level of burden (relative to intention to treat (ITT))
Cutpoint Method Level of burden
Heavy Medium Mild None
0.9 PP 0.788 0.982 1.052 1.028
AT 0.749 0.983 1.052 1.017
IV 2.977 3.269 1.710 1.184
0.85 PP 0.776 0.950 1.019 1.028
AT 0.742 0.933 1.014 1.009
IV 2.647 2.629 1.531 1.175
0.8 PP 0.752 0.909 1.006 1.020
AT 0.711 0.886 0.994 1.009
IV 2.362 2.195 1.421 1.175
0.75 PP 0.729 0.905 1.000 1.028
AT 0.690 0.886 0.979 1.015
IV 2.110 1.894 1.347 1.167
0.7 PP 0.715 0.883 1.001 1.021
AT 0.679 0.865 0.984 1.015
IV 1.915 1.647 1.289 1.159
0.65 PP 0.694 0.870 0.996 1.021
AT 0.662 0.858 0.985 1.008
IV 1.728 1.468 1.243 1.152
0.6 PP 0.686 0.860 0.985 1.013
AT 0.656 0.852 0.970 1.008
IV 1.560 1.336 1.213 1.144
0.55 PP 0.669 0.859 0.981 1.014
AT 0.636 0.856 0.971 1.001
IV 1.413 1.235 1.179 1.144
0.5 PP 0.665 0.854 0.970 1.013
AT 0.629 0.842 0.957 1.000
IV 1.291 1.158 1.147 1.144
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known methods not designed for the situation. These is-
sues apply to employing noncompliance methods in the
factorial design setting as well. The investigation and de-
velopment of methods designed for use in both partial
compliance and factorial design settings is the subject of
future work.
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